Alpha Cognition Appoints Experienced Biopharma CFO Bethany Sensenig to Board of Directors
Summary
Alpha Cognition Inc. appointed Bethany Sensenig, a seasoned biopharmaceutical CFO and operations executive, to its Board of Directors, enhancing the board's financial and strategic expertise.
Key Events
-
New Director Appointed
Bethany Sensenig, an experienced biopharmaceutical executive, was appointed to the Board of Directors on April 15, 2026.
-
Extensive Financial & Operational Background
Ms. Sensenig previously served as CFO and Head of Operations at Radius Health, Inc., CFO and Interim CEO at 9 Meters Biopharma, and held senior finance and commercial operations roles at Biogen Inc., bringing significant expertise in growth, financial performance, and M&A.
-
Standard Director Compensation
In connection with her appointment, Ms. Sensenig received an initial grant of 5,489 restricted stock units and 6,991 stock options with an exercise price of $6.65 per share, both vesting one year after the grant date.
Analysis
Alpha Cognition Inc. has strengthened its board with the appointment of Bethany Sensenig, a highly experienced biopharmaceutical executive. Her background as CFO and Head of Operations at commercial-stage companies like Radius Health, Inc., and her extensive tenure at Biogen Inc., brings critical financial and operational expertise. This appointment is a positive development for corporate governance and strategic oversight, especially following the company's recent 2025 annual report which disclosed a material weakness and increased cash burn. Her experience in growth, financial performance, and M&A could be instrumental in guiding the company's future.
At the time of this filing, ACOG was trading at $6.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150M. The 52-week trading range was $3.97 to $11.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.